Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in pediatric chronic graft-versus-host disease (Phase 1/2, open-label, Japan)
jRCT2031260072Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Primary endpoints: Phase 1: AUC at steady state and Phase 2: Overall response rate by Week 25/Cycle 7 Day 1. Started Apr 2026; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2031260072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260072.